Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

2 days ago · Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025. In the past year, shares of Amicus have plunged 31.6% compared with the …

6%
OFF

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

2 weeks from now

2 days ago · Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025. In the past year, shares of Amicus have plunged 31.6% compared with the …

yahoo.com

32%
OFF

Amicus Therapeutics Reports Preliminary 2024 Revenue And

2 weeks from now

2 days ago · Total revenue in 2024 reached $528.5 million (preliminary and unaudited), representing a year-over-year increase of 32%, reflecting strong operational growth of 32% at …

globenewswire.com

24%
OFF

Amicus Therapeutics Reports Preliminary 2024 Revenue And …

2 weeks from now

2 days ago · Total Revenue Growth of 17-24% at CER Expected in 2025 >3,000 People Treated with an Amicus Therapy Today 2. PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- …

marketscreener.com

$0.01
OFF

Amicus Therapeutics Reports Mixed Q1 Results; Updates FY24 …

2 weeks from now

More on Amicus Therapeutics Amicus Therapeutics: Expect Improved Commercial Momentum In 2024 Amicus Therapeutics Non-GAAP EPS of $0.01 beats by $0.05, revenue of $115.08M in-line

msn.com

37%
OFF

Amicus Therapeutics Announces Third Quarter 2024 Financial …

2 weeks from now

Nov 6, 2024 · Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-YearGalafold® Q3 Revenue of $120.4M, up 20% Year-over-YearPombiliti® + Opfolda® Q3 Reve...

businessinsider.com

$528
OFF

Amicus Therapeutics Reports Preliminary 2024 Revenue And …

2 weeks from now

5 days ago · FOLD Amicus Therapeutics Inc Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook. 2024 Total Revenue of $528M, Representing …

advfn.com

FAQs about Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook Coupon?

How will amicus (fold) perform in 2024?

Amicus remains focused on delivering Galafold revenue growth of 11-16% at CER in 2024. The company is also looking to ensure the successful global launches of Pombiliti and Opfolda in Pompe disease. Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024. ...

What are the key strategic priorities for Amicus in 2024?

Amicus is focused on the following key strategic priorities in 2024: 1 At constant exchange rates (CER). In order to illustrate underlying performance, Amicus discusses its results in terms of CER growth. This represents growth calculated as if the exchange rates had remained unchanged from those used in the comparative period. ...

What time is Amicus Therapeutics conference call & webcast?

Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2024. ...

What's going on with Amicus Therapeutics fold?

Amicus Therapeutics FOLD announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold (migalastat), which is approved for treating Fabry disease and Pombiliti + Opfolda. ...

Why did Amicus file a patent lawsuit with Teva Pharmaceuticals TEVA?

In October 2024, Amicus signed a licensing agreement with Teva Pharmaceuticals TEVA, resolving the patent lawsuit FOLD filed earlier. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold 123 mg capsules before the related patents expired. ...

Will 2025 be a better year than 2024?

Perhaps because the poll was conducted with Biden still in office, just 16% of Republicans say the nation’s economy is good right now. But they see positive change on the horizon: About 7 in 10 Republicans say 2025 will be a better year than 2024 for the U.S. economy. ...